text stringlengths 198 2.89k |
|---|
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
and other entities purchasing from the SDs and SP at a discounted price. The SDs and SP charge back to the Company the difference between the price initially paid by the SDs and SP and the discounte... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
and co-pay amounts paid using data provided by third-party administrators. If actual amounts differ from the original estimates the assumptions being applied are updated and adjustment for prior per... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
returns is based on the on-hand channel inventory data and sell-through data obtained from the SDs and SP. In arriving at its estimate, the Company also considers historical product returns, the und... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
1,035
(553)
1,916
Balance at Beginning of Year
Provision for Current Period Sales
Payments
Balance at March 31, 2022
For the Three Months Ended March 31, 2022
407
407
Revenue Under License ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
distinct in the context of the contract; (iii) determines the transaction price, including the constraint on variable consideration; (iv) allocates the transaction price to the performance obligatio... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment, all other fees the Company may earn under such l... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
revenue in the future. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the estim... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
, share-based compensation expense, contract services, and other external development expenses. Aadi Bioscience, Inc. records research and development activities conducted by third-party service prov... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
known, the Company adjusts its accrued expenses.
Share-Based Compensation
Aadi Bioscience, Inc. recognizes all share-based payments to employees, including grants of employee stock options in the ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
feitures are recognized and accounted for as they occur.
Due to the historical lack of a public market for the trading of the Company’s securities and a lack of company-specific historical and impli... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
the average of the contractual term of the stock option and its weighted-average vesting period,
to calculate the expected term, as it does not have sufficient historical exercise data to provide a... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
a straight-line basis by recognizing the grant date fair value over the associated service period of the award, which is generally the vesting term.
Employee Stock Purchase Plan
Stock-based compen... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recov... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
position, as well as consideration of the available facts and circumstances. Aadi Bioscience, Inc. recognizes interest and penalties related to uncertain tax positions, if any exist, in income tax e... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
.0001 per share.
Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares and common share equivalents outs... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
arrants to purchase common stock
29
29
Recent Accounting Pronouncements
In August 2020, the FASB issued ASU 2020-06, “
Debt – Debt with Conversion and Other Options”
(Subtopic 470-20) and “Deri... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
2023, including interim periods within those fiscal years for smaller reporting companies. Aadi Bioscience, Inc. is currently evaluating the impact the adoption of ASU 2020-06 will have on the Compa... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
clarify, improve, or defer the adoption of ASU 2016-13. Aadi Bioscience, Inc. adopted ASU 2016-13 beginning in January 2023. Aadi Bioscience, Inc. determined that the adoption of this standard did n... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
government treasury bills
50,076
50,076
Commercial paper
47,233
47,233
Corporate bonds
4,260
4,260
Government agency
15,559
15,559
Total financial assets
73,730
67,052
140,782
13
Ta... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
287
Total financial assets
102,743
62,833
165,576
(1)
Included in cash and cash equivalents in the accompanying condensed consolidated balance sheets.
As of March 31, 2023, net unrealized loss... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
.S. government treasury bills
Less than 1
50,101
(26)
50,075
Commercial paper
Less than 1
47,233
47,233
Corporate bonds
Less than 1
4,280
(20)
4,260
Government agency
Less than 1
15,5... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
108)
70,708
Commercial paper
Less than 1
53,296
53,296
Corporate bonds
Less than 1
4,276
(26)
4,250
Government agency
Less than 1
5,272
15
5,287
Total
165,691
19
(134)
165,576
5.... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
-lived contract intangible asset as a result of the Merger, related to the license agreement, dated June 24, 2018, with Gossamer Bio, Inc. (“Gossamer”), as amended (the “Gossamer License Agreement”),... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
carrying amount. At the effective time of the Merger, the Company recognized an impairment of $74.2 million to bring the carrying amount of the contract intangible asset down to its estimated fair v... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
”). The useful life of the intangible asset was estimated to be approximately 14.3 years.
On April 25, 2022, the Company received a formal notice of termination from Gossamer for the Gossamer Licens... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
the Company fully impaired the intangible asset, $3.7 million, of which the Gossamer License Agreement is the underlying asset, during the year ended December 31, 2022.
There was no amortization ex... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
,463
Accrued clinical
1,333
2,399
Accrued contract manufacturing
898
405
Advanced customer payments
1,571
Accrued other - sales related
1,150
1,435
Accrued other
584
536
Total accrued ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
2021, the Company exercised its option to extend the term of the Pacific Palisades Lease for an additional three-year period and entered into an amendment to the lease agreement (the “Pacific Palisa... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
in Morristown, New Jersey (the “Morristown Lease”). The Morristown Lease has a term of seventy-three months, unless terminated sooner, and includes rent abatement for the first three months and the ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
,267
Total operating lease liabilities
1,568
1,661
15
Table of Contents
Rent expense
for the three months ended March 31, 2023 and 2022 is presented on the following table (in thousands):
Thr... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
are summarized below (in thousands):
Future Minimum Lease Payments:
2023
377
2024
512
2025
320
2026
231
2027
280
Thereafter
110
Total minimum lease payments
1,830
Less: amount repres... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
”) with BMS for exclusive rights for certain patents and a non-exclusive license for certain technology and know-how pertaining to FYARRO.
The BMS License Agreement will remain in effect from the ef... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
ended March 31, 2023 and 2022, royalties on net product sales were $0.4 million and $0.2 million, respectively. No payments related to milestones were paid during the three months ended March 31, 20... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
investment in public equity financing (the “2021 PIPE Financing”). Pursuant to the terms of the Amendment, the remaining previously outstanding payment obligation of $5.8 million, is due on the thir... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
based on net sales of products subject to the BMS License Agreement.
EOC License Agreement
On December 8, 2020, the Company entered into a license agreement (“EOC License Agreement”) with EOC Phar... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
June 27, 2022, the Company received written notice from EOC that EOC elected to terminate the EOC License Agreement, effective immediately, due to alleged material breaches by the Company under such... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
had the right to terminate the EOC License Agreement in the event that the other party breaches the agreement and fails to cure the breach, becomes insolvent or challenges certain of the intellectua... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
OC License Agreement were considered variable consideration and were constrained with respect to revenue recognition notification from EOC that the milestone and royalty payments had been achieved.
... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
0001 per share under the Company's certificate of incorporation, as amended and restated. As of March 31, 2023 and December 31, 2022, the shares of common stock outstanding were 24,436,990 and 24,435... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
3.0% of the aggregate gross proceeds from each sale of shares of common stock under the Sales Agreement. As of
March 31, 2023
, no shares of common stock had been sold pursuant to the Sales Agreem... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
shares of the Company's common stock (the "Pre-Funded Warrants") at a purchase price of $12.4999 per Pre-Funded Warrant. The Pre-Funded Warrants are exercisable at an exercise price of $0.0001 and w... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
Agreement, including the shares issuable upon the exercise of the Pre-Funded Warrants, that are not then registered on an effective registration statement, pursuant to a registration statement filed... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
the holders of common stock are entitled to share ratably in the Company’s assets.
Voting
The holders of common stock are entitled to one vote for each share of common stock held at all meetings o... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock unit awards and other stock awards. In connection with the closing of the Merger and th... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
2017 Stock Option and Incentive Plan (the “2017 Plan,” and together with the 2011 Plan, the “Prior Plans”). No new awards will be granted under the Prior Plans effective as of the closing of the Mer... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
provision described below, a total of 2,070,784 shares of common stock were initially reserved for issuance pursuant to the 2021 Plan. In addition, the shares reserved for issuance under the 2021 Pl... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
this sentence is 764,154 shares).
The number of shares available for issuance under the 2021 Plan also will include an annual increase, or the evergreen feature, on the first day of each of the Com... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
uable under the 2021 Plan are authorized, but unissued, or reacquired shares of common stock. If an award expires or becomes unexercisable without having been exercised in full, is surrendered pursua... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
,997 shares were outstanding under the Private Aadi Plan, 2017 Plan and 2021 Plan, respectively. As of March 31, 2023, no shares were outstanding under the 2011 Plan.
The following table summarizes ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
,581)
20.20
Outstanding as of March 31, 2023
3,846,365
16.51
8.73
1,259
Options exercisable as of March 31, 2023
851,373
18.56
6.81
1,127
Vested and expected to vest as of March 31, 2023
... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
57 and $14.80 per share, respectively.
As of March 31, 2023, there was $30.9 million of unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted av... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
employee share-based compensation activity for the periods presented (in thousands):
Three Months Ended March 31,
2023
2022
Selling, general and administrative
1,640
1,101
Research and develop... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
$8.57
$14.80
Risk-free interest rate
3.42% - 4.17%
1.46% - 1.76%
Expected volatility
89.94% - 95.72%
85.99% - 86.25%
Expected term (in years)
5.8 - 6.1
6.1
Expected dividend yield
Merger ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
000 shares (after taking into account the reverse stock split of the Company’s common stock at a ratio of 15:1 effected on August 26, 2021 immediately prior to the closing of the Merger, (the "Revers... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
-dilution events such as stock splits, combinations, reorganizations, or issue shares as part of a stock dividend.
The warrants meet the criteria to be classified within stockholders’ equity.
11. E... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
4.40%
Expected volatility
92.59% - 105.68%
Expected term (in years)
0.5
Expected dividend yield
As of March 31, 2023, and
December 31, 2022,
736,711 and 492,361 shares of common stock were av... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
respectively.
12. Income Taxes
Aadi Bioscience, Inc. recorded income tax expense of zero for the
three months ended
March 31, 2023 and 2022, respectively. Aadi Bioscience, Inc. continues to main... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
OC claims that the Company breached certain provisions of the EOC License Agreement, including failing to provide certain manufacturing information to EOC.
As a result, EOC is seeking monetary damag... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
and $2.8 million for expenditures incurred by clinical and contract manufacturing vendors as of March 31, 2023, and December 31, 2022, respectively.
At March 31, 2023, the Company had one significa... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
ib, a KRAS
G12C
selective inhibitor, and FYARRO in KRAS
G12C
mutant non-small cell lung cancer (NSCLC) and other solid tumors. Under the terms of the agreement, Mirati will be responsible for spo... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
agrasib and FYARRO in combination in patients both with and without prior exposure to a KRAS
G12C
inhibitor. The trial will build on preclinical data showing enhanced anti-tumor efficacy with the c... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are based on our management’s belief and assumptions and on inf... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
advanced malignant perivascular epithelioid cell tumors (“PEComa”), or to obtain and maintain regulatory approval for FYARRO in additional indications, or any other product candidates we may develop... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
and reimbursement of FYARRO and any other product candidates we may develop in the future, if approved;
the rate and degree of market acceptance of FYARRO and any other product candidates we may de... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
our ability to develop and advance product candidates into, and successfully complete, clinical studies;
the implementation of our business model and our strategic plans for our business;
our abili... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
FYARRO in additional indications and any other product candidates we may develop in the future;
the period over which we anticipate our existing cash and cash equivalents will be sufficient to fund... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
hire and retain additional qualified professionals;
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and
other factors including but not l... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
their use in the negative) intended to identify forward-looking statements although not all forward-looking statements contain these identifying words. Actual results could differ materially from th... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
of future performance. You should read this Quarterly Report and the documents that we reference in this Quarterly Report and have filed with or furnished to the U.S. Securities and Exchange Commiss... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
to the date of this Quarterly Report.
References in the following discussion to
we,
our,
us,
or
Aadi
refer to Aadi Bioscience, Inc. and its subsidiaries.
24
Table of Contents
Item 2. Manag... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
discussion and analysis including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risk, uncertainties and assumptions. Our actua... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statemen... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site.
In November 2021, the U.S. Food and Drug Administration (the “... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
In addition to advanced malignant PEComa, based on exploratory data from our completed Phase 2 registrational study, Advanced Malignant PEComa Trial (“AMPECT”), and our expanded access program for FY... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
PRECISION 1 trial, enrollment is well-balanced, the trial is accruing evenly between the
TSC1
and
TSC2
arms, and more than 15 discreet tumor types have been enrolled with no more than three of a... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
("BMS") for $4.1 billion in August 2022.
Leadership Transition. Effective January 1, 2023, our board of directors appointed Brendan Delaney, our former Chief Operating Officer, to President and Ch... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
Mr. Giacobello will continue to serve in his role as Chief Financial Officer in addition to his role as Interim Chief Executive Officer and President. In addition, Dr. Desai, the founder of the comp... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
, Inc. (“Mirati”) to evaluate the combination of Mirati’s adagrasib, a KRAS
G12C
selective inhibitor, and FYARRO in KRAS
G12C
mutant non-small cell lung cancer (NSCLC) and other solid tumors. Und... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
. In addition, the study will investigate the safety, tolerability and efficacy of adagrasib and FYARRO in combination in patients both with and without prior exposure to a KRAS
G12C
inhibitor. The... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
BioScience, LLC, a wholly owned subsidiary of Celgene Corporation, which is a wholly owned subsidiary of BMS. Under the BMS License Agreement, BMS is entitled to receive certain development mileston... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
50% of the previously outstanding payment obligation under the agreement, following the effective time of the 2021 Private Investment in Public Equity (PIPE) Financing ("2021 PIPE Financing") that oc... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
to licensor, is due on the third anniversary of the effective time of such 2021 PIPE Financing plus any accrued and unpaid interest due thereon.
EOC License Agreement
In December 2020, we entered ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
recognized $2.8 million of license expense in the fourth quarter of 2020 and had a corresponding $2.8 million sublicense payable to BMS as of December 31, 2020, which was paid in 2021.
During the f... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
from EOC that EOC has elected to terminate the EOC License Agreement, effective immediately. On June 27, 2022, EOC filed a Request for Arbitration with the International Chamber of Commerce’s Intern... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
be impacted by a number of challenging global and national events and circumstances that continue to evolve, including the recent turmoil in the global banking system, public health epidemics, such ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
impacts that these various events and circumstances may have on our business and we take steps, where warranted, to minimize any potential negative impacts on our business resulting from these event... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
we have experienced some supply disruptions due to the COVID-19 pandemic, including closures at certain chip manufacturers, which led to extended lead times for FYARRO and diversion of certain lab m... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
-19 pandemic, our clinical trials have been, and may continue to be, affected by the closure of offices, lack of resources or closure of borders, among other measures being put in place around the wo... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. At this point, the extent to which these global... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
.9 million during the three months ended March 31, 2023.
We have built a cross-functional commercial team consisting of marketing, market access and commercial operations and will continue to strate... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
relative to 2022, as a result of significant expenses related to the PRECISION 1 trial which was open to enrollment during the year ended December 31, 2022, with the first patient dosed in March 202... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
million of cash, cash equivalents and short-term investments. Based on our current plans, we believe our existing cash, cash equivalents and short-term investments will enable us to conduct our plan... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
outside the United States and in additional indications and any other product candidates we may develop in the future and the commercial launch of FYARRO
Basis of Presentation
The following discus... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
Consolidated Statements of Operations and Comprehensive Loss
Revenue
Product Sales, Net
FYARRO was approved by the FDA in November 2021. On February 22, 2022, we launched sales of FYARRO to speci... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
AC”). Distribution fees are recorded as an offset to product sales based on contractual terms at the time the sale is recognized.
Rebates: Allowance for rebates include mandated discounts under the ... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
activity. If actual future rebates vary from estimates, we may need to adjust prior period accruals, which would affect product sales in the period of adjustment.
Chargebacks: Chargebacks are disco... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
at the time of product sale to the SDs and SP based on estimated patient participation and average co-pay benefit to be paid per a claim. Our estimated amounts are compared to actual program partici... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
a patient. As we receive inventory reports from the SDs and SP and have the ability to control the amount of product that is sold to the SDs and SP, we estimate future potential product returns base... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
services, insurance costs, intellectual property and patent costs, facility costs and travel costs. We expect that selling, general and administrative expenses will increase in the future as we expa... |
YOU are a financial analyst. You are reading a report of a company.
The report is about the company's financial status.
development expenses consist primarily of: (i) employee related costs, including salaries, benefits and share-based compensation expense for employees engaged in scientific research and development ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.